Theres no doubt thatGlaxoSmithKlines(LSE: GSK) (NYSE: GSK.US) future is uncertain. After being accused of using bribes to sell its treatments within several markets, the biotechnology giant is now under investigation by the Serious Fraud Office. Unfortunately, if the SFO decides to make an example of Glaxo, the company could be Read More...

Sell in May and dont come back until St. Ledgers day is a well-known saying in investing circles. Indeed, data from recent decades seems to back it up: the stock market rarely embarks on a sustained summer rally and usually falls between May and September. This has been the case Read More...

Today I am outlining why Banco Santander (LSE: BNC) (NYSE: SAN.US) could be considered an attractive addition to any stocks portfolio. Peachy prices given current growth estimates Of course, Santander like the rest of the banking sector saw earnings plummet in the years following the global recession of five years Read More...

With the FTSE 100 still hovering around all-time highs, its getting hard to find any shares out there thattrade at an attractive valuation. However, I believe I have found five gems:Afren (LSE: AFR),Sainsbury (LSE: SBRY),Petrofac (LSE: PFC),BP (LSE: BP) andTate & Lyle (LSE: TATE), all of which currently look undervalued. Read More...

The aerospace and defence sector is going through a tough patch of late, with recession across the Western world leading to cuts in defence spending in the US, UK and across Europe. But perhaps surprisingly, share prices have generally been beating the FTSE. In fact, Rolls-Royce (LSE: RR) (NASDAQOTH: RYCEY.US) Read More...

2014 has been little short of a disaster for Barclays (LSE: BARC). The share price of the bank has fallen by 19%, its full-year forecasts have been downgraded and the company has been accused of fraud with regard to its dark pool trading operations. Still, it remains hugely profitable and Read More...